Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline
Abstract Objective This systematic review update synthesized recent evidence on the benefits and harms of breast cancer screening in women aged ≥ 40 years and aims to inform the Canadian Task Force on Preventive Health Care’s (CTFPHC) guideline update. Methods We searched Ovid MEDLINE® ALL, Embase C...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Systematic Reviews |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13643-024-02700-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850244459365662720 |
|---|---|
| author | Alexandria Bennett Nicole Shaver Niyati Vyas Faris Almoli Robert Pap Andrea Douglas Taddele Kibret Becky Skidmore Martin Yaffe Anna Wilkinson Jean M. Seely Julian Little David Moher |
| author_facet | Alexandria Bennett Nicole Shaver Niyati Vyas Faris Almoli Robert Pap Andrea Douglas Taddele Kibret Becky Skidmore Martin Yaffe Anna Wilkinson Jean M. Seely Julian Little David Moher |
| author_sort | Alexandria Bennett |
| collection | DOAJ |
| description | Abstract Objective This systematic review update synthesized recent evidence on the benefits and harms of breast cancer screening in women aged ≥ 40 years and aims to inform the Canadian Task Force on Preventive Health Care’s (CTFPHC) guideline update. Methods We searched Ovid MEDLINE® ALL, Embase Classic + Embase and Cochrane Central Register of Controlled Trials to update our searches to July 8, 2023. Search results for observational studies were limited to publication dates from 2014 to capture more relevant studies. Screening was performed independently and in duplicate by the review team. To expedite the screening process, machine learning was used to prioritize relevant references. Critical health outcomes, as outlined by the CTFPHC, included breast cancer and all-cause mortality, treatment-related morbidity and overdiagnosis. Randomized controlled trials (RCTs), non/quasi RCTs and observational studies were included. Data extraction and quality assessment were performed by one reviewer and verified by another. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool for RCTs and the Joanna Brigg’s Institute (JBI) checklists for non-randomized and observational studies. When deemed appropriate, studies were pooled via random-effects models. The overall certainty of the evidence was assessed following GRADE guidance. Results Three new papers reporting on existing RCT trial data and 26 observational studies were included. No new RCTs were identified in this update. No study reported results by ethnicity, race, proportion of study population with dense breasts, or socioeconomic status. For breast cancer mortality, RCT data from the prior review reported a significant relative reduction in the risk of breast cancer mortality with screening mammography for a general population of 15% (RR 0.85 95% CI 0.78 to 0.93). In this review update, the breast cancer mortality relative risk reduction based on RCT data remained the same, and absolute effects by age decade over 10 years were 0.27 fewer deaths per 1000 in those aged 40 to 49; 0.50 fewer deaths per 1000 in those aged 50 to 59; 0.65 fewer deaths per 1000 in those aged 60 to 69; and 0.92 fewer deaths per 1000 in those aged 70 to 74. For observational data, the relative mortality risk reduction ranged from 29 to 62%. Absolute effects from breast cancer mortality over 10 years ranged from 0.79 to 0.94 fewer deaths per 1000 in those aged 40 to 49; 1.45 to 1.72 fewer deaths per 1000 in those aged 50 to 59; 1.89 to 2.24 fewer deaths per 1000 in those aged 60 to 69; and 2.68 to 3.17 fewer deaths per 1000 in those aged 70 to 74. For all-cause mortality, RCT data from the prior review reported a non-significant relative reduction in the risk of all-cause mortality of screening mammography for a general population of 1% (RR 0.99, 95% CI 0.98 to 1.00). In this review update, the absolute effects for all-cause mortality over 10 years by age decade were 0.13 fewer deaths per 1000 in those aged 40 to 49; 0.31 fewer deaths per 1000 in those aged 50 to 59; 0.71 fewer deaths per 1000 in those aged 60 to 69; and 1.41 fewer deaths per 1000 in those aged 70 to 74. No observational data were found for all-cause mortality. For overdiagnosis, this review update found the absolute effects for RCT data (range of follow-up between 9 and 15 years) to be 1.95 more invasive and in situ cancers per 1000, or 1 more invasive cancer per 1000, for those aged 40 to 49 and 1.93 more invasive and in situ cancers per 1000, or 1.18 more invasive cancers per 1000, for those aged 50 to 59. A sensitivity analysis removing high risk of bias studies found 1.57 more invasive and in situ cancers, or 0.49 more invasive cancers, per 1000 for those aged 40 to 49 and 3.95 more invasive and in situ cancers per 1000, or 2.81 more invasive cancers per 1000, in those aged 50 to 59. For observational data, one report (follow-up for 13 years) found 0.34 more invasive and in situ cancers per 1000 in those aged 50 to 69. Overall, the GRADE certainty of evidence was assessed as low or very low, suggesting that the evidence is very uncertain about the effect of screening for breast cancer on the outcomes evaluated in this review. Conclusions This systematic review update did not identify any new trials comparing breast cancer screening to no screening. Although 26 new observational studies were identified, the overall quality of evidence remains generally low or very low. Future research initiatives should prioritize studying screening in higher risk populations such as those from different ages, racial or ethnic groups, with dense breasts or family history. Systematic review registration: Protocol available on the Open Science Framework: https://osf.io/xngsu/ |
| format | Article |
| id | doaj-art-43f05085d3834a0fbde183479974fa88 |
| institution | OA Journals |
| issn | 2046-4053 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Systematic Reviews |
| spelling | doaj-art-43f05085d3834a0fbde183479974fa882025-08-20T01:59:43ZengBMCSystematic Reviews2046-40532024-12-0113112610.1186/s13643-024-02700-3Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guidelineAlexandria Bennett0Nicole Shaver1Niyati Vyas2Faris Almoli3Robert Pap4Andrea Douglas5Taddele Kibret6Becky Skidmore7Martin Yaffe8Anna Wilkinson9Jean M. Seely10Julian Little11David Moher12School of Epidemiology and Public Health, Faculty of Medicine, University of OttawaSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaPatient Partner RepresentativeSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaIndependent Information SpecialistPhysical Sciences Program, Sunnybrook Research Institute and Ontario Institute for Cancer ResearchDepartment of Family Medicine, University of OttawaDepartment of Radiology, University of Ottawa, Ottawa Hospital Research InstituteSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaClinical Epidemiology Program, Ottawa Hospital Research InstituteAbstract Objective This systematic review update synthesized recent evidence on the benefits and harms of breast cancer screening in women aged ≥ 40 years and aims to inform the Canadian Task Force on Preventive Health Care’s (CTFPHC) guideline update. Methods We searched Ovid MEDLINE® ALL, Embase Classic + Embase and Cochrane Central Register of Controlled Trials to update our searches to July 8, 2023. Search results for observational studies were limited to publication dates from 2014 to capture more relevant studies. Screening was performed independently and in duplicate by the review team. To expedite the screening process, machine learning was used to prioritize relevant references. Critical health outcomes, as outlined by the CTFPHC, included breast cancer and all-cause mortality, treatment-related morbidity and overdiagnosis. Randomized controlled trials (RCTs), non/quasi RCTs and observational studies were included. Data extraction and quality assessment were performed by one reviewer and verified by another. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool for RCTs and the Joanna Brigg’s Institute (JBI) checklists for non-randomized and observational studies. When deemed appropriate, studies were pooled via random-effects models. The overall certainty of the evidence was assessed following GRADE guidance. Results Three new papers reporting on existing RCT trial data and 26 observational studies were included. No new RCTs were identified in this update. No study reported results by ethnicity, race, proportion of study population with dense breasts, or socioeconomic status. For breast cancer mortality, RCT data from the prior review reported a significant relative reduction in the risk of breast cancer mortality with screening mammography for a general population of 15% (RR 0.85 95% CI 0.78 to 0.93). In this review update, the breast cancer mortality relative risk reduction based on RCT data remained the same, and absolute effects by age decade over 10 years were 0.27 fewer deaths per 1000 in those aged 40 to 49; 0.50 fewer deaths per 1000 in those aged 50 to 59; 0.65 fewer deaths per 1000 in those aged 60 to 69; and 0.92 fewer deaths per 1000 in those aged 70 to 74. For observational data, the relative mortality risk reduction ranged from 29 to 62%. Absolute effects from breast cancer mortality over 10 years ranged from 0.79 to 0.94 fewer deaths per 1000 in those aged 40 to 49; 1.45 to 1.72 fewer deaths per 1000 in those aged 50 to 59; 1.89 to 2.24 fewer deaths per 1000 in those aged 60 to 69; and 2.68 to 3.17 fewer deaths per 1000 in those aged 70 to 74. For all-cause mortality, RCT data from the prior review reported a non-significant relative reduction in the risk of all-cause mortality of screening mammography for a general population of 1% (RR 0.99, 95% CI 0.98 to 1.00). In this review update, the absolute effects for all-cause mortality over 10 years by age decade were 0.13 fewer deaths per 1000 in those aged 40 to 49; 0.31 fewer deaths per 1000 in those aged 50 to 59; 0.71 fewer deaths per 1000 in those aged 60 to 69; and 1.41 fewer deaths per 1000 in those aged 70 to 74. No observational data were found for all-cause mortality. For overdiagnosis, this review update found the absolute effects for RCT data (range of follow-up between 9 and 15 years) to be 1.95 more invasive and in situ cancers per 1000, or 1 more invasive cancer per 1000, for those aged 40 to 49 and 1.93 more invasive and in situ cancers per 1000, or 1.18 more invasive cancers per 1000, for those aged 50 to 59. A sensitivity analysis removing high risk of bias studies found 1.57 more invasive and in situ cancers, or 0.49 more invasive cancers, per 1000 for those aged 40 to 49 and 3.95 more invasive and in situ cancers per 1000, or 2.81 more invasive cancers per 1000, in those aged 50 to 59. For observational data, one report (follow-up for 13 years) found 0.34 more invasive and in situ cancers per 1000 in those aged 50 to 69. Overall, the GRADE certainty of evidence was assessed as low or very low, suggesting that the evidence is very uncertain about the effect of screening for breast cancer on the outcomes evaluated in this review. Conclusions This systematic review update did not identify any new trials comparing breast cancer screening to no screening. Although 26 new observational studies were identified, the overall quality of evidence remains generally low or very low. Future research initiatives should prioritize studying screening in higher risk populations such as those from different ages, racial or ethnic groups, with dense breasts or family history. Systematic review registration: Protocol available on the Open Science Framework: https://osf.io/xngsu/https://doi.org/10.1186/s13643-024-02700-3Breast cancerScreeningMammographySystematic reviewMortalityOverdiagnosis |
| spellingShingle | Alexandria Bennett Nicole Shaver Niyati Vyas Faris Almoli Robert Pap Andrea Douglas Taddele Kibret Becky Skidmore Martin Yaffe Anna Wilkinson Jean M. Seely Julian Little David Moher Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline Systematic Reviews Breast cancer Screening Mammography Systematic review Mortality Overdiagnosis |
| title | Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline |
| title_full | Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline |
| title_fullStr | Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline |
| title_full_unstemmed | Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline |
| title_short | Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline |
| title_sort | screening for breast cancer a systematic review update to inform the canadian task force on preventive health care guideline |
| topic | Breast cancer Screening Mammography Systematic review Mortality Overdiagnosis |
| url | https://doi.org/10.1186/s13643-024-02700-3 |
| work_keys_str_mv | AT alexandriabennett screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT nicoleshaver screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT niyativyas screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT farisalmoli screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT robertpap screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT andreadouglas screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT taddelekibret screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT beckyskidmore screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT martinyaffe screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT annawilkinson screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT jeanmseely screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT julianlittle screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline AT davidmoher screeningforbreastcancerasystematicreviewupdatetoinformthecanadiantaskforceonpreventivehealthcareguideline |